Cargando…

Urate Lowering Therapy with Febuxostat in Daily Practice—A Multicentre, Open-Label, Prospective Observational Study

Introduction. Febuxostat, a novel xanthine oxidase inhibitor for the treatment of symptomatic hyperuricemia, showed superiority over allopurinol in the reduction of serum uric acid levels in pivotal studies. Whether this holds true the FORTE (febuxostat in the oral urate lowering treatment: effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tausche, Anne-Kathrin, Reuss-Borst, Monika, Koch, Ute
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167949/ https://www.ncbi.nlm.nih.gov/pubmed/25276138 http://dx.doi.org/10.1155/2014/123105

Ejemplares similares

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A, et al.
Publicado: (2015)

Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study
por: Yamanaka, Hisashi, et al.
Publicado: (2018)

Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort
por: Liang, Nan, et al.
Publicado: (2019)

Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A., et al.
Publicado: (2015)

Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis
por: Kim, Sang-Hyon, et al.
Publicado: (2020)

Hidden gout- Ultrasound findings in patients with musculo-skeletal problems and hyperuricemia
por: Reuss-Borst, Monika A, et al.
Publicado: (2014)

Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study
por: Yu, K-H, et al.
Publicado: (2016)

Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine
por: Watanabe, Hirohisa, et al.
Publicado: (2020)

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population
por: Raal, Frederick, et al.
Publicado: (2007)

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study
por: Shiramoto, Masanari, et al.
Publicado: (2018)

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
por: MacDonald, Thomas M, et al.
Publicado: (2014)

Febuxostat methanol solvate
por: Jiang, Qi-Ying, et al.
Publicado: (2011)

Febuxostat ethanol monosolvate
por: Gelbrich, Thomas, et al.
Publicado: (2020)

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience
por: Sulaiman, Narisa, et al.
Publicado: (2017)

Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial
por: Saag, Kenneth G., et al.
Publicado: (2022)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Predictors of response to viscosupplementation in patients with hip osteoarthritis: results of a prospective, observational, multicentre, open-label, pilot study
por: Eymard, Florent, et al.
Publicado: (2017)

An Open‐Label Dose‐Finding Study of Allopurinol to Target Defined Reduction in Urate Levels in Hemodialysis Patients
por: Rutherford, Elaine, et al.
Publicado: (2017)

Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial
por: Mukri, Mohd Noor Azreey, et al.
Publicado: (2018)

Febuxostat and the Black Box Blues
por: Abeles, Aryeh M., et al.
Publicado: (2019)

Factors associated with initiation and persistence of urate-lowering therapy
por: Dehlin, Mats, et al.
Publicado: (2017)

Review of Urate-Lowering Therapeutics: From the Past to the Future
por: Jenkins, Christopher, et al.
Publicado: (2022)

The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study
por: Badawy, Sherif M., et al.
Publicado: (2021)

The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
por: Pang, Lei, et al.
Publicado: (2023)

A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout
por: Lee, Joondon, et al.
Publicado: (2023)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia
por: Chen, Mo, et al.
Publicado: (2020)

Nachhaltige Steigerung der Aktivität durch Rehabilitation
por: Reuß-Borst, Monika, et al.
Publicado: (2022)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
por: Wrigley, Rebekah, et al.
Publicado: (2020)

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
por: Dalbeth, Nicola, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mk5tdeei357bo735mids4qg76l